Clinical Trial Update: This Study Tests Different Doses of BI 1015550 in Patients With Idiopathic Pulmonary Fibrosis (IPF). The Study Tests How BI 1015550 is Taken up by the Body and How Well it is Tolerated. [Phase 1]

View source ↗

Summary

This Phase 1 trial evaluates different doses of BI 1015550 in idiopathic pulmonary fibrosis, focusing on pharmacokinetics and tolerability.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• BI-1015550 (BI-1015550)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Idiopathic Pulmonary Fibrosis | Phase 1 | Status: COMPLETED | Results posted: 2025-11-28